NCT03735121 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 39
- group Id
- BG003
- value
- 124
- group Id
- BG004
- value
- 247
- group Id
- BG005
- value
- 438
- units
- Participants
- groups
- description
- Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
- id
- BG000
- title
- Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg
- description
- Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
- id
- BG001
- title
- Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg
- description
- Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
- id
- BG002
- title
- Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg
- description
- Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
- id
- BG003
- title
- Part 2: Atezolizumab IV 1200 mg
- description
- Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
- id
- BG004
- title
- Part 2: Atezolizumab SC 1875 mg
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 58
- group Id
- BG004
- value
- 137
- group Id
- BG005
- value
- 229
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 66
- group Id
- BG004
- value
- 110
- group Id
- BG005
- value
- 209
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 42
- group Id
- BG004
- value
- 72
- group Id
- BG005
- value
- 140
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 82
- group Id
- BG004
- value
- 175
- group Id
- BG005
- value
- 298
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 24
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 33
- group Id
- BG004
- value
- 47
- group Id
- BG005
- value
- 85
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 74
- group Id
- BG004
- value
- 174
- group Id
- BG005
- value
- 303
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 11
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 9
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 36
- group Id
- BG004
- value
- 61
- group Id
- BG005
- value
- 115
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 88
- group Id
- BG004
- value
- 185
- group Id
- BG005
- value
- 314
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 8
- title
- Not Stated
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- title
- Unknown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Part 1: Intent-to-treat (ITT) population included all enrolled participants. Part 2: Full analysis set (FAS) included all participants who were randomized with participants grouped per their assigned treatment. HCPs who administered the study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, the HCPs were asked to complete 2 questionnaires. No baseline data were collected for the HCPs in this study.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 39
- group Id
- BG003
- value
- 124
- group Id
- BG004
- value
- 247
- group Id
- BG005
- value
- 438
- units
- Participants
- groups
- description
- Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
- id
- BG000
- title
- Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg
- description
- Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
- id
- BG001
- title
- Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg
- description
- Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
- id
- BG002
- title
- Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg
- description
- Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
- id
- BG003
- title
- Part 2: Atezolizumab IV 1200 mg
- description
- Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
- id
- BG004
- title
- Part 2: Atezolizumab SC 1875 mg
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 58
- group Id
- BG004
- value
- 137
- group Id
- BG005
- value
- 229
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 66
- group Id
- BG004
- value
- 110
- group Id
- BG005
- value
- 209
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 42
- group Id
- BG004
- value
- 72
- group Id
- BG005
- value
- 140
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 82
- group Id
- BG004
- value
- 175
- group Id
- BG005
- value
- 298
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 24
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 33
- group Id
- BG004
- value
- 47
- group Id
- BG005
- value
- 85
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 74
- group Id
- BG004
- value
- 174
- group Id
- BG005
- value
- 303
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 11
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 9
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 36
- group Id
- BG004
- value
- 61
- group Id
- BG005
- value
- 115
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 88
- group Id
- BG004
- value
- 185
- group Id
- BG005
- value
- 314
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 8
- title
- Not Stated
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- title
- Unknown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Part 1: Intent-to-treat (ITT) population included all enrolled participants. Part 2: Full analysis set (FAS) included all participants who were randomized with participants grouped per their assigned treatment. HCPs who administered the study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, the HCPs were asked to complete 2 questionnaires. No baseline data were collected for the HCPs in this study.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle